Physician profile
Ali A Berry
NPI 1427009729
$4,854.45
in general payments reported to CMS, 2019-2025
31 companies · $755 in 2025
The $755 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $266 · 2021: $590 · 2022: $806 · 2023: $653 · 2024: $1,016 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.62 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,047.36 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $552.01 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $457.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $441.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $342.62 | 2019-2024 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $241.80 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $227.49 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $223.90 | 2019-2025 | |
| Leo Pharma INC. | $194.18 | 2022-2025 | Adbry |
| Incyte Corporation | $124.78 | 2022-2024 | Opzelura |
| Amgen INC. | $115.85 | 2019-2025 | Otezla |
| Botanix Sb INC | $102.08 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.12 | 2019-2021 | |
| Dermavant Sciences, INC. | $80.52 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $65.75 | 2021-2024 | Poteligeo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.89 | 2023-2024 | Olumiant, Taltz |
| Prugen, INC. Pharmaceuticals | $51.55 | 2019 | |
| Celgene Corporation | $49.92 | 2019 | |
| Ucb, INC. | $49.35 | 2024 | Bimzelx |
| Boston Scientific Corporation | $46.04 | 2022-2024 | Varithena Administration Pack |
| Galderma Laboratories, L.P. | $45.84 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $38.88 | 2024 | Zoryve |
| Strata Skin Sciences, INC. | $33.39 | 2025 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.18 | 2023 | Spevigo |
| Mallinckrodt Hospital Products INC. | $24.20 | 2025 | Acthar |
| Biofrontera INC. | $23.28 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kerecis Limited | $23.05 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dermira, INC. | $18.96 | 2020 | |
| Mylan Institutional INC. | $18.68 | 2023 | Hulio |
| Almirall LLC | $17.00 | 2023 | Seysara |
| Epi Health, LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.